A Phase 2 Trial of Filanesib in Relapsed/Refractory Multiple Myeloma (AfFIRM)

Clinical Trial ID NCT02092922

PubWeight™ 3.20‹?›

🔗 Visit the ClinicalTrials.gov page for NCT02092922

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Promising therapies in multiple myeloma. Blood 2015 0.89
2 Evolving paradigms in the treatment of relapsed/refractory multiple myeloma: increased options and increased complexity. Bone Marrow Transplant 2016 0.82
3 Trial Watch-Immunostimulation with cytokines in cancer therapy. Oncoimmunology 2015 0.77
4 Salvage therapies in relapsed and/or refractory myeloma: what is current and what is the future? Onco Targets Ther 2016 0.76
Next 100